Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: Besifloxacin is a novel fluoroquinolone antibiotic developed to provide alternative coverage for ocular pathogens with current and emerging in vitro and in vivo resistance to present fluoroquinolones and other commonly dispensed ocular antibiotics. The purpose of this study was to investigate the in vitro efficacy of besifloxacin and 7 comparators against ciprofloxacin- and methicillin-susceptible and nonsusceptible staphylococcal isolates from conjunctivitis, blepharitiis, keratitis, endophthalmitis, and other ocular surface disorders. Methods: Nonconsecutive ocular Staphylococcus aureus (N=154) and Coagulase-negative Staphylococcus (N=89, including 84 Staphylococcus epidermidis) isolates collected from patients presenting during the 6 years (2003-2008) were evaluated using frozen minimal inhibitory concentration (MIC) panels containing serial dilutions (μg/mL) of besifloxacin (0.004-32), moxifloxacin (0.004-128), ciprofloxacin (0.03-256), azithromycin (0.12-128), oxacillin (0.03-32), gentamicin (0.03-128), trimethoprim (0.5-16), and vancomycin (0.12-32). Results: Among the fluoroquinolones group, besifloxacin had the lowest MIC90s. MIC90 values (μg/mL) for besifloxacin (4) was 8-fold lower than for moxifloxacin (32) and 32-fold lower than ciprofloxacin (128). Among the nonfluoroquinolone comparators, vancomycin (2) had the lowest MICs followed by gentamicin (16) and trimethoprim (16). Besifloxacin MIC90s (μg/mL) were lowest for isolates recovered from the lacrimal sac (0.25), followed by lids (1), conjunctiva (2), keratitis (4), and intraocular fluids (4). Conclusions: Due to its improved coverage for ciprofloxacin- and methicillin-resistant staphylococci, besifloxacin may offer extended coverage for some ocular pathogens resistant to current fluoroquinolones recovered from a diverse group of ocular sources. Ninety-five percent of all isolates were covered by a besifloxacin MIC90 of 4 μg/mL.

Original languageEnglish
Pages (from-to)339-344
Number of pages6
JournalJournal of Ocular Pharmacology and Therapeutics
Volume29
Issue number3
DOIs
StatePublished - Apr 1 2013

Fingerprint

Methicillin
Ciprofloxacin
Staphylococcus
Fluoroquinolones
Trimethoprim
Keratitis
Vancomycin
Gentamicins
Nasolacrimal Duct
Anti-Bacterial Agents
Oxacillin
Azithromycin
Methicillin Resistance
Endophthalmitis
Conjunctivitis
Staphylococcus epidermidis
In Vitro Techniques
7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
Aqueous Humor
Coagulase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Ophthalmology
  • Pharmacology

Cite this

@article{4dc294baed8542c0be0b93a9d1536063,
title = "Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci",
abstract = "Purpose: Besifloxacin is a novel fluoroquinolone antibiotic developed to provide alternative coverage for ocular pathogens with current and emerging in vitro and in vivo resistance to present fluoroquinolones and other commonly dispensed ocular antibiotics. The purpose of this study was to investigate the in vitro efficacy of besifloxacin and 7 comparators against ciprofloxacin- and methicillin-susceptible and nonsusceptible staphylococcal isolates from conjunctivitis, blepharitiis, keratitis, endophthalmitis, and other ocular surface disorders. Methods: Nonconsecutive ocular Staphylococcus aureus (N=154) and Coagulase-negative Staphylococcus (N=89, including 84 Staphylococcus epidermidis) isolates collected from patients presenting during the 6 years (2003-2008) were evaluated using frozen minimal inhibitory concentration (MIC) panels containing serial dilutions (μg/mL) of besifloxacin (0.004-32), moxifloxacin (0.004-128), ciprofloxacin (0.03-256), azithromycin (0.12-128), oxacillin (0.03-32), gentamicin (0.03-128), trimethoprim (0.5-16), and vancomycin (0.12-32). Results: Among the fluoroquinolones group, besifloxacin had the lowest MIC90s. MIC90 values (μg/mL) for besifloxacin (4) was 8-fold lower than for moxifloxacin (32) and 32-fold lower than ciprofloxacin (128). Among the nonfluoroquinolone comparators, vancomycin (2) had the lowest MICs followed by gentamicin (16) and trimethoprim (16). Besifloxacin MIC90s (μg/mL) were lowest for isolates recovered from the lacrimal sac (0.25), followed by lids (1), conjunctiva (2), keratitis (4), and intraocular fluids (4). Conclusions: Due to its improved coverage for ciprofloxacin- and methicillin-resistant staphylococci, besifloxacin may offer extended coverage for some ocular pathogens resistant to current fluoroquinolones recovered from a diverse group of ocular sources. Ninety-five percent of all isolates were covered by a besifloxacin MIC90 of 4 μg/mL.",
author = "Darlene Miller and Chang, {Jonathan S.} and Flynn, {Harry W} and Alfonso, {Eduardo C}",
year = "2013",
month = "4",
day = "1",
doi = "10.1089/jop.2012.0081",
language = "English",
volume = "29",
pages = "339--344",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci

AU - Miller, Darlene

AU - Chang, Jonathan S.

AU - Flynn, Harry W

AU - Alfonso, Eduardo C

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Purpose: Besifloxacin is a novel fluoroquinolone antibiotic developed to provide alternative coverage for ocular pathogens with current and emerging in vitro and in vivo resistance to present fluoroquinolones and other commonly dispensed ocular antibiotics. The purpose of this study was to investigate the in vitro efficacy of besifloxacin and 7 comparators against ciprofloxacin- and methicillin-susceptible and nonsusceptible staphylococcal isolates from conjunctivitis, blepharitiis, keratitis, endophthalmitis, and other ocular surface disorders. Methods: Nonconsecutive ocular Staphylococcus aureus (N=154) and Coagulase-negative Staphylococcus (N=89, including 84 Staphylococcus epidermidis) isolates collected from patients presenting during the 6 years (2003-2008) were evaluated using frozen minimal inhibitory concentration (MIC) panels containing serial dilutions (μg/mL) of besifloxacin (0.004-32), moxifloxacin (0.004-128), ciprofloxacin (0.03-256), azithromycin (0.12-128), oxacillin (0.03-32), gentamicin (0.03-128), trimethoprim (0.5-16), and vancomycin (0.12-32). Results: Among the fluoroquinolones group, besifloxacin had the lowest MIC90s. MIC90 values (μg/mL) for besifloxacin (4) was 8-fold lower than for moxifloxacin (32) and 32-fold lower than ciprofloxacin (128). Among the nonfluoroquinolone comparators, vancomycin (2) had the lowest MICs followed by gentamicin (16) and trimethoprim (16). Besifloxacin MIC90s (μg/mL) were lowest for isolates recovered from the lacrimal sac (0.25), followed by lids (1), conjunctiva (2), keratitis (4), and intraocular fluids (4). Conclusions: Due to its improved coverage for ciprofloxacin- and methicillin-resistant staphylococci, besifloxacin may offer extended coverage for some ocular pathogens resistant to current fluoroquinolones recovered from a diverse group of ocular sources. Ninety-five percent of all isolates were covered by a besifloxacin MIC90 of 4 μg/mL.

AB - Purpose: Besifloxacin is a novel fluoroquinolone antibiotic developed to provide alternative coverage for ocular pathogens with current and emerging in vitro and in vivo resistance to present fluoroquinolones and other commonly dispensed ocular antibiotics. The purpose of this study was to investigate the in vitro efficacy of besifloxacin and 7 comparators against ciprofloxacin- and methicillin-susceptible and nonsusceptible staphylococcal isolates from conjunctivitis, blepharitiis, keratitis, endophthalmitis, and other ocular surface disorders. Methods: Nonconsecutive ocular Staphylococcus aureus (N=154) and Coagulase-negative Staphylococcus (N=89, including 84 Staphylococcus epidermidis) isolates collected from patients presenting during the 6 years (2003-2008) were evaluated using frozen minimal inhibitory concentration (MIC) panels containing serial dilutions (μg/mL) of besifloxacin (0.004-32), moxifloxacin (0.004-128), ciprofloxacin (0.03-256), azithromycin (0.12-128), oxacillin (0.03-32), gentamicin (0.03-128), trimethoprim (0.5-16), and vancomycin (0.12-32). Results: Among the fluoroquinolones group, besifloxacin had the lowest MIC90s. MIC90 values (μg/mL) for besifloxacin (4) was 8-fold lower than for moxifloxacin (32) and 32-fold lower than ciprofloxacin (128). Among the nonfluoroquinolone comparators, vancomycin (2) had the lowest MICs followed by gentamicin (16) and trimethoprim (16). Besifloxacin MIC90s (μg/mL) were lowest for isolates recovered from the lacrimal sac (0.25), followed by lids (1), conjunctiva (2), keratitis (4), and intraocular fluids (4). Conclusions: Due to its improved coverage for ciprofloxacin- and methicillin-resistant staphylococci, besifloxacin may offer extended coverage for some ocular pathogens resistant to current fluoroquinolones recovered from a diverse group of ocular sources. Ninety-five percent of all isolates were covered by a besifloxacin MIC90 of 4 μg/mL.

UR - http://www.scopus.com/inward/record.url?scp=84874958092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874958092&partnerID=8YFLogxK

U2 - 10.1089/jop.2012.0081

DO - 10.1089/jop.2012.0081

M3 - Article

C2 - 23289847

AN - SCOPUS:84874958092

VL - 29

SP - 339

EP - 344

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 3

ER -